143 related articles for article (PubMed ID: 29534659)
21. Management of Plasma Cell-Rich Acute Rejection in Living-Related Kidney Transplant: Role of Proteasome Inhibitor.
Abbas K; Mubarak M; Zafar MN; Musharraf W; Imam M; Aziz T; Rizvi AH
Exp Clin Transplant; 2019 Feb; 17(1):42-46. PubMed ID: 29534661
[TBL] [Abstract][Full Text] [Related]
22. Nodular B-cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab.
Lehnhardt A; Mengel M; Pape L; Ehrich JH; Offner G; Strehlau J
Am J Transplant; 2006 Apr; 6(4):847-51. PubMed ID: 16539643
[TBL] [Abstract][Full Text] [Related]
23. CD20+ lymphocytes in renal allografts are associated with poor graft survival in pediatric patients.
Tsai EW; Rianthavorn P; Gjertson DW; Wallace WD; Reed EF; Ettenger RB
Transplantation; 2006 Dec; 82(12):1769-73. PubMed ID: 17198274
[TBL] [Abstract][Full Text] [Related]
24. Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies.
Halloran PF; Reeve JP; Pereira AB; Hidalgo LG; Famulski KS
Kidney Int; 2014 Feb; 85(2):258-64. PubMed ID: 23965521
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic analysis of acute vascular rejection cases after renal transplantation.
Shimizu T; Tanabe T; Omoto K; Ishida H; Tanabe K
Transplant Proc; 2012 Jan; 44(1):230-5. PubMed ID: 22310621
[TBL] [Abstract][Full Text] [Related]
26. Probable C4d-negative accelerated acute antibody-mediated rejection due to non-HLA antibodies.
Niikura T; Yamamoto I; Nakada Y; Kamejima S; Katsumata H; Yamakawa T; Furuya M; Mafune A; Kobayashi A; Tanno Y; Miki J; Yamada H; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():75-8. PubMed ID: 26031592
[TBL] [Abstract][Full Text] [Related]
27. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
28. B cells in cluster or in a scattered pattern do not correlate with clinical outcome of renal allograft rejection.
Scheepstra C; Bemelman FJ; van der Loos C; Rowshani AT; van Donselaar-Van der Pant KA; Idu MM; ten Berge IJ; Florquin S
Transplantation; 2008 Sep; 86(6):772-8. PubMed ID: 18813100
[TBL] [Abstract][Full Text] [Related]
29. Borderline Changes on Dysfunctional Renal Allograft Biopsies: Clinical Relevance in a Living Related Renal Transplant Setting.
Mubarak M; Shakeel S; Abbas K; Aziz T; Zafar MN; Naqvi SA; Rizvi SA
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):24-27. PubMed ID: 28260426
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of late antibody-mediated rejection (C4d-mediated rejection): a single-center experience.
Tatar E; Uslu A; Simsek C; Vardar E
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():259-62. PubMed ID: 25894167
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
[TBL] [Abstract][Full Text] [Related]
32. The impact of C4d staining as a humoral injury marker.
Kara M; Demir F; Ata P; Ozel L; Gumrukcu G; Unal E; Canbakan M; Gucun M; Esadoglu V; Ozdemir E; Cemel H; Titiz MI
Transplant Proc; 2012; 44(6):1694-6. PubMed ID: 22841245
[TBL] [Abstract][Full Text] [Related]
33. Designation of T-cell-mediated rejection type Ib and IIa reflects the type of rejection rather than the severity in the Banff classification.
Wu K; Budde K; Schmidt D; Neumayer HH; Rudolph B
Exp Clin Transplant; 2014 Oct; 12(5):415-23. PubMed ID: 25299369
[TBL] [Abstract][Full Text] [Related]
34. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.
Kabei K; Uchida J; Iwai T; Yamasaki T; Kuwabara N; Naganuma T; Kumada N; Nakatani T
Transpl Immunol; 2014 Aug; 31(2):92-7. PubMed ID: 24932811
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M
Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599
[TBL] [Abstract][Full Text] [Related]
36. Subclinical antibody-mediated rejection due to anti-human-leukocyte-antigen-DR53 antibody accompanied by plasma cell-rich acute rejection in a patient with cadaveric kidney transplantation.
Katsuma A; Yamamoto I; Komatsuzaki Y; Niikura T; Kawabe M; Okabayashi Y; Yamakawa T; Katsumata H; Nakada Y; Kobayashi A; Tanno Y; Miki J; Yamada H; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():31-4. PubMed ID: 26971538
[TBL] [Abstract][Full Text] [Related]
37. Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.
Sinangil A; Ucar ZA; Koc Y; Barlas S; Abouzahir S; Ecder ST; Akin EB
Transplant Proc; 2019 Sep; 51(7):2268-2273. PubMed ID: 31358450
[TBL] [Abstract][Full Text] [Related]
38. Antibody-mediated rejection and treatment in pediatric patients: one center's experience.
Gulleroglu K; Baskin E; Bayrakci US; Turan M; Ozdemir BH; Moray G; Karakayali H; Haberal M
Exp Clin Transplant; 2013 Oct; 11(5):404-7. PubMed ID: 24128133
[TBL] [Abstract][Full Text] [Related]
39. Living-donor kidney transplant in T-cell and B-cell flow cytometry crossmatch-positive patients.
Terasaka S; Kitada H; Okabe Y; Kawanami S; Noguchi H; Miyamoto K; Tsuchimoto A; Masutani K; Tanaka M
Exp Clin Transplant; 2014 Jun; 12(3):227-32. PubMed ID: 24907723
[TBL] [Abstract][Full Text] [Related]
40. Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection.
Rovira J; Ramírez-Bajo MJ; Banon-Maneus E; Lazo-Rodríguez M; Moya-Rull D; Hierro-Garcia N; Tubita V; Piñeiro GJ; Revuelta I; Ventura-Aguiar P; Cucchiari D; Oppenheimer F; Brunet M; Campistol JM; Diekmann F
Transplantation; 2018 Jul; 102(7):1075-1084. PubMed ID: 29620612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
